Goto K - Search Results

1

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K. Kohno T, et al. Among authors: goto k. Transl Lung Cancer Res. 2015 Apr;4(2):156-64. doi: 10.3978/j.issn.2218-6751.2014.11.11. Transl Lung Cancer Res. 2015. PMID: 25870798 Free PMC article. Review.

2

Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma.

Yoh K, Goto K, Ishii G, Niho S, Ohmatsu H, Kubota K, Kakinuma R, Nagai K, Suga M, Nishiwaki Y. Yoh K, et al. Among authors: goto k. Cancer. 2003 Sep 1;98(5):926-31. doi: 10.1002/cncr.11606. Cancer. 2003. PMID: 12942558 Free article.

3

Cushing's syndrome associated with adenocarcinoma of the lung.

Yoh K, Kubota K, Nomura M, Niho S, Goto K, Ohmatsu H, Kakinuma R, Nishiwaki Y. Yoh K, et al. Among authors: goto k. Intern Med. 2003 Sep;42(9):831-3. doi: 10.2169/internalmedicine.42.831. Intern Med. 2003. PMID: 14518671 Free article.

4

Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.

Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M, Ochiai A. Yoh K, et al. Among authors: goto k. Clin Cancer Res. 2004 Mar 1;10(5):1691-7. doi: 10.1158/1078-0432.ccr-0937-3. Clin Cancer Res. 2004. PMID: 15014021

5

High body mass index correlates with increased risk of venous irritation by vinorelbine infusion.

Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y. Yoh K, et al. Among authors: goto k. Jpn J Clin Oncol. 2004 Apr;34(4):206-9. doi: 10.1093/jjco/hyh029. Jpn J Clin Oncol. 2004. PMID: 15121757

6

Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung.

Kim YH, Ishii G, Goto K, Nagai K, Tsuta K, Shiono S, Nitadori J, Kodama T, Nishiwaki Y, Ochiai A. Kim YH, et al. Among authors: goto k. Clin Cancer Res. 2004 Nov 1;10(21):7311-7. doi: 10.1158/1078-0432.CCR-04-0811. Clin Cancer Res. 2004. PMID: 15534107

7

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.

Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, Saijo N, Nishiwaki Y. Niho S, et al. Among authors: goto k. J Clin Oncol. 2006 Jan 1;24(1):64-9. doi: 10.1200/JCO.2005.02.5825. J Clin Oncol. 2006. PMID: 16382114 Clinical Trial.

8

Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.

Niho S, Goto K, Yoh K, Kim YH, Ohmatsu H, Kubota K, Saijo N, Nishiwaki Y. Niho S, et al. Among authors: goto k. Jpn J Clin Oncol. 2006 May;36(5):269-73. doi: 10.1093/jjco/hyl021. Epub 2006 May 15. Jpn J Clin Oncol. 2006. PMID: 16702163

9

Association of polymorphisms in the MTH1 gene with small cell lung carcinoma risk.

Kohno T, Sakiyama T, Kunitoh H, Goto K, Nishiwaki Y, Saito D, Hirose H, Eguchi T, Yanagitani N, Saito R, Sasaki-Matsumura R, Mimaki S, Toyama K, Yamamoto S, Kuchiba A, Sobue T, Ohta T, Ohki M, Yokota J. Kohno T, et al. Among authors: goto k. Carcinogenesis. 2006 Dec;27(12):2448-54. doi: 10.1093/carcin/bgl095. Epub 2006 Jun 14. Carcinogenesis. 2006. PMID: 16774934

10

Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy.

Saijo T, Ishii G, Ochiai A, Yoh K, Goto K, Nagai K, Kato H, Nishiwaki Y, Saijo N. Saijo T, et al. Among authors: goto k. Lung Cancer. 2006 Nov;54(2):217-25. doi: 10.1016/j.lungcan.2006.06.018. Epub 2006 Aug 24. Lung Cancer. 2006. PMID: 16934364

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,632 results

Search Page